Novavax Statistics
Total Valuation
Novavax has a market cap or net worth of $1.03 billion. The enterprise value is $528.93 million.
Important Dates
The next estimated earnings date is Thursday, August 7, 2025, before market open.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Novavax has 161.97 million shares outstanding. The number of shares has increased by 41.51% in one year.
| Current Share Class | 161.97M |
| Shares Outstanding | 161.97M |
| Shares Change (YoY) | +41.51% |
| Shares Change (QoQ) | +10.85% |
| Owned by Insiders (%) | 0.50% |
| Owned by Institutions (%) | 49.84% |
| Float | 136.65M |
Valuation Ratios
The trailing PE ratio is 2.12.
| PE Ratio | 2.12 |
| Forward PE | n/a |
| PS Ratio | 0.79 |
| Forward PS | 1.81 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 1.10 |
| EV / Sales | 0.42 |
| EV / EBITDA | 1.13 |
| EV / EBIT | 1.25 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.06
| Current Ratio | 2.06 |
| Quick Ratio | 1.78 |
| Debt / Equity | n/a |
| Debt / EBITDA | 0.49 |
| Debt / FCF | n/a |
| Interest Coverage | 19.50 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 19.97% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 48.55% |
| Revenue Per Employee | $1.32M |
| Profits Per Employee | $502,833 |
| Employee Count | 952 |
| Asset Turnover | 0.95 |
| Inventory Turnover | 40.12 |
Taxes
In the past 12 months, Novavax has paid $9.82 million in taxes.
| Income Tax | 9.82M |
| Effective Tax Rate | 2.01% |
Stock Price Statistics
The stock price has decreased by -51.41% in the last 52 weeks. The beta is 2.77, so Novavax's price volatility has been higher than the market average.
| Beta (5Y) | 2.77 |
| 52-Week Price Change | -51.41% |
| 50-Day Moving Average | 6.73 |
| 200-Day Moving Average | 8.54 |
| Relative Strength Index (RSI) | 42.28 |
| Average Volume (20 Days) | 5,824,413 |
Short Selling Information
The latest short interest is 44.48 million, so 27.46% of the outstanding shares have been sold short.
| Short Interest | 44.48M |
| Short Previous Month | 44.70M |
| Short % of Shares Out | 27.46% |
| Short % of Float | 32.55% |
| Short Ratio (days to cover) | 4.04 |
Income Statement
In the last 12 months, Novavax had revenue of $1.25 billion and earned $478.70 million in profits. Earnings per share was $2.97.
| Revenue | 1.25B |
| Gross Profit | 732.56M |
| Operating Income | 422.81M |
| Pretax Income | n/a |
| Net Income | 478.70M |
| EBITDA | 467.50M |
| EBIT | 422.81M |
| Earnings Per Share (EPS) | $2.97 |
Full Income StatementBalance Sheet
The company has $731.48 million in cash and $228.66 million in debt, giving a net cash position of $502.82 million or $3.10 per share.
| Cash & Cash Equivalents | 731.48M |
| Total Debt | 228.66M |
| Net Cash | 502.82M |
| Net Cash Per Share | $3.10 |
| Equity (Book Value) | -75.64M |
| Book Value Per Share | -0.47 |
| Working Capital | 445.86M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$189.21 million and capital expenditures -$7.40 million, giving a free cash flow of -$196.61 million.
| Operating Cash Flow | -189.21M |
| Capital Expenditures | -7.40M |
| Free Cash Flow | -196.61M |
| FCF Per Share | -$1.21 |
Full Cash Flow StatementMargins
Gross margin is 58.37%, with operating and profit margins of 33.69% and 38.14%.
| Gross Margin | 58.37% |
| Operating Margin | 33.69% |
| Pretax Margin | 38.93% |
| Profit Margin | 38.14% |
| EBITDA Margin | 37.25% |
| EBIT Margin | 33.69% |
| FCF Margin | n/a |
Dividends & Yields
Novavax does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -41.51% |
| Shareholder Yield | -41.51% |
| Earnings Yield | 46.40% |
| FCF Yield | -19.06% |
Analyst Forecast
The average price target for Novavax is $16.60, which is 160.60% higher than the current price. The consensus rating is "Buy".
| Price Target | $16.60 |
| Price Target Difference | 160.60% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | -10.00% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 10, 2019. It was a reverse split with a ratio of 0.05:1.
| Last Split Date | May 10, 2019 |
| Split Type | Reverse |
| Split Ratio | 0.05:1 |
Scores
Novavax has an Altman Z-Score of -1.71 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.71 |
| Piotroski F-Score | 5 |